Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogs

The melanocortin‐4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 administered subcutaneously to healthy dogs. Dogs were treated with high‐ (2.25 mg kg(−1)) (n = 5) and low‐...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Pharmacol Res Perspect
Main Authors: Axiak‐Bechtel, Sandra M., Leach, Stacey B., Scholten, David G., Newton‐Northup, Jessica R., Johnson, Brendan J., Durham, H. E., Gruber, Kenneth A., Callahan, Michael F.
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2021
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8135083/
https://ncbi.nlm.nih.gov/pubmed/34014033
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.777
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker